fda tirzepatide shortage resolved 2025 Semaglutide and No Longer in Shortage: All You Need to Know Compounders lose battle over Eli

Advertised $279/mo lands closer to $349 once the full plan applies

The use of SGLT-2 inhibitors has become SoC in people with CKD and T2D in Denmark (as recommended by the Danish Endocrinology Society [DES]), due to the associated kidney-protective effects, but use was relatively low during the FLOW trial [14, 15, 57]

Fats provide 9 calories per gram versus 4 for protein and carbs, dramatically increasing caloric density

The failure of next-generation candidates to demonstrate significant advantages over existing therapies, as seen with Novo Nordisk's CagriSema trial miss in reasserting a clear efficacy edge, could also limit future premium pricing